trending Market Intelligence /marketintelligence/en/news-insights/trending/RPv28xsr15-2Wp8LEnGudA2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

TG Therapeutics begins US rolling submission of blood cancer therapy

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

TG Therapeutics begins US rolling submission of blood cancer therapy

TG Therapeutics Inc. began its rolling submission with the U.S. Food and Drug Administration to market its medicine umbralisib as a treatment for two types of blood cancers.

The New York-based biopharmaceutical company is looking to market umbralisib as a treatment for marginal zone lymphoma and follicular lymphoma in patients who did not get better after receiving prior treatment. The drug has the FDA's orphan-drug and breakthrough-therapy designations in the marginal zone lymphoma indication.

The company said it began a single rolling submission, which is expected to be completed in the first half of the year.

TG Therapeutics' executive chairman and CEO, Michael Weiss, said the company is also working to advance other medicines, including a drug called ublituximab to treat multiple sclerosis. The company is also studying umbralisib as a treatment for newer indications.